Report of Foreign Issuer (6-k)
July 28 2017 - 8:35AM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
July 2017
Commission
File Number 1-15182
DR. REDDYS LABORATORIES LIMITED
(Translation of registrants name into English)
8-2-337, Road
No. 3, Banjara Hills
Hyderabad, Telangana 500 034, India
+91-40-49002900
(Address
of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Note:
Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached
annual report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(7): ☐
Note:
Regulation S-T Rule 101(b)(7) only permits the submission in paper of a
Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the
registrants home country), or under the rules of the home country exchange on which the registrants securities are traded, as long as the report or other document is not a press release, is not required to be and has not been
distributed to the registrants security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ☐ No ☒
If Yes is marked, indicate below the file number assigned to registrant in connection with Rule 12g3-2(b):
82-
.
EXHIBITS
|
|
|
Exhibit Number
|
|
Description of Exhibits
|
|
|
99.1
|
|
Press Release, Dr. Reddys and CHD Bioscience Announce Global License and Commercialization Agreement for Phase III Clinical Trial Candidate for Mitigation of Surgical Site Infections, dated July 27,
2017.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
DR. REDDYS LABORATORIES LIMITED
(Registrant)
|
|
|
|
|
Date: July 28, 2017
|
|
|
|
By:
|
|
/s/ Sandeep Poddar
|
|
|
|
|
Name:
|
|
Sandeep Poddar
|
|
|
|
|
Title:
|
|
Company Secretary
|
Dr Reddys Laboratories (NYSE:RDY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Dr Reddys Laboratories (NYSE:RDY)
Historical Stock Chart
From Sep 2023 to Sep 2024